Different patterns of beta-catenin expression in gastric carcinomas: relationship with clinicopathological parameters and prognostic outcome (original) (raw)

Abstract

Different patterns of b-catenin expression in gastric carcinomas: relationship with clinicopathological parameters and prognostic outcome Aims: The cadherin±catenin complex is known to play a critical role in maintenance of cell adhesion. Additionally b-catenin (b-ct) can also take part in signal transduction and nuclear b-ct expression could be correlated with poor prognosis in several malignancies. Since, in gastric cancer, this role of b-ct is still uncertain, we investigated the expression pattern of b-ct as well as the possible prognostic role. Methods and results: b-catenin expression was immunohistochemically investigated in a retrospective series of 401 R0-resected gastric carcinomas. Out of these cases, 54 tumours (13.5%) revealed a preserved membranous b-ct expression similar to that in normal gastric mucosa. In 80 tumours b-ct expression was moderately reduced and in 117 tumours highly reduced. In 150 tumours (37.4%), no or only a weak membranous b-ct expression was found. Additionally, in 53 tumours, a strong b-ct expression could be observed in the cytoplasm with a simultaneous nuclear b-ct immunoreactivity in 17 of these 53 tumours, while nine tumours only showed nuclear immunore-activity without cytoplasmic staining. There were no signi®cant correlations between the degree of membranous b-ct expression or the different staining pattern (membranous vs. cytoplasmic/nuclear) and the grade of tumour differentiation, the histological tumour type according to Lauren, as well as with the prognostic parameters pT, pN category and vascular invasion. No associations could be found with tumour cell proliferation and the expression of E-cadherin, irrespectively of the different b-ct staining pattern. Univariate analysis revealed no in¯uence on survival, either for membranous or for cytoplasmic/nuclear b-ct expression. Conclusion: Our data on 401 tumours suggest that activation of the Wnt/b-catenin signalling does also occur in a subset of gastric carcinomas. However, in gastric cancer, neither the presence of cytoplasmic/ nuclear b-ct expression nor the reduction or loss of membranous b-ct expression is correlated with a speci®c histological tumour type, tumour progression or prognosis.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (44)

  1. Lipponen P, Saarelainen E, Ji H, Aaltomaa S, Syrja Ènen K. Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer. J. Pathol. 1994; 174; 101±109.
  2. Bringuier PP, Umbas R, Schaafsma E, Karthaus HFM, Debruyne FMJ, Schalken JA. Decreased E-cadherin immunoreactivity cor- relates with poor survival in patients with bladder tumours. Cancer Res. 1993; 53; 3241±3245.
  3. Umbas R, Isaacs WB, Bringuier PP et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 1994; 54; 3929±3933.
  4. Krishnadath KK, Tilanus HW, van Blankenstein M et al. Reduced expression of the cadherin±catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J. Pathol. 1997; 182; 331±338.
  5. Gabbert HE, Mu È ller W, Schneiders A et al. Prognostic value of E-cadherin expression in 413 gastric carcinomas. Int. J. Cancer 1996; 69; 184±189.
  6. Ozawa M, Baribault H, Kemler R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three inde- pendent proteins structurally related in different species. EMBO J. 1989; 8; 1711±1717.
  7. Zheng Z, Pan J, Chu B, Wong YC, Cheung AL, Tsao SW. Downregulation and abnormal expression of E-cadherin and beta-catenin in nasopharyngeal carcinoma: close association with advanced disease stage and lymph node metastasis. Hum. Pathol. 1999; 30; 458±466.
  8. Retera JM, Leers MP, Sulzer MA, Theunissen PH. The expression of beta-catenin in non-small-cell lung cancer: a clinicopatholog- ical study. J. Clin. Pathol. 1998; 51; 891±894.
  9. Peralta Soler A, Knudsen KA, Salazar H, Han AC, Keshgegian AA. P-cadherin expression in breast carcinoma indicates poor survival. Cancer 1999; 86; 1263±1272.
  10. Bankfalvi A, Terpe HJ, Breukelmann D et al. Immunophenotypic and prognostic analysis of E-cadherin and b-catenin expression during breast carcinogenesis and tumour progression: a com- parative study with CD44. Histopathology 1999; 34; 25±34.
  11. Gunther K, Brabletz T, Kraus C et al. Predictive value of nuclear b-catenin expression for the occurrence of distant metastases in rectal cancer. Dis. Colon Rectum 1998; 41; 1256±1261.
  12. Shimazui T, Schalken JA, Giroldi LA et al. Prognostic value of cadherin-associated molecules (a, b-, and c-catenins and p120cas) in bladder tumours. Cancer Res. 1996; 56; 4154±4158.
  13. Mialhe A, Louis J, Montlevier S et al. Expression of E-cadherin and a-, b-and c-catenins in human bladder carcinomas: are they good prognostic factors? Invasion Metastasis 1997; 17; 124±137.
  14. Nakanishi Y, Ochiai A, Akimoto S et al. Expression of E-cadherin, a-catenin, b-catenin and plakoglobin in esophageal carcinomas and its prognostic signi®cance. Oncology 1997; 54; 158±165.
  15. Hink L, Nelson WJ, Papkoff J. Wnt-1 modulates cell±cell adhesion in mammalian cells by stabilizing b-catenin binding to the cell adhesion protein cadherin. J. Cell Biol. 1994; 124; 729±741.
  16. Peifer M. Regulating cell proliferation: as easy as APC. Science 1996; 272; 974±975.
  17. Morin PJ, Sparks AB, Korinek V et al. Activation of b-catenin-Tcf signaling in colon cancer by mutations in b-catenin or APC. Science 1997; 275; 1787±1790.
  18. Korinek V, Barker N, Morin PJ et al. Constitutive transcriptional activation by a b-catenin±Tcf complex in APC -/-colon carcinoma. Science 1997; 275; 1784±1787.
  19. He TC, Sparks AB, Rago C et al. Identi®cation of c-myc as a target of the APC pathway. Science 1998; 281; 1509±1512.
  20. Tetsu O, McCormick F. b-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398; 422±426.
  21. Rubinfeld B, Albert I, Por®ri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3 (to the APC±b-catenin complex and regulation of complex assembly. Science 1996; 272; 1023±1026.
  22. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Por®ri E, Polakis P. Stabilization of b-catenin by genetic defects in melanoma cell lines. Science 1997; 275; 1790±1792.
  23. Inomata M, Ochiai A, Akimoto S, Kitano S, Hirohashi S. Alteration of b-catenin expression in colonic epithelial cells of familial polyposis patients. Cancer Res. 1996; 56; 2213±2217.
  24. Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Sua Ârez A, Armas A. b-catenin expression pattern in stage I and II ovarian carcinomas. Relationship with b-catenin gene mutations, clinico- pathological features, and clinical outcome. Am. J. Pathol. 1999; 155; 527±536.
  25. Jawhari A, Jordan S, Poole S, Browne P, Pignatelli M, Farthing MJ. Abnormal immunoreactivity of the E-cadherin±catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology 1997; 112; 46±57.
  26. Ramesh S, Nash J, McCulloch PG. Reduction in membranous expression of beta-catenin and increased cytoplasmic E-cadherin expression predict poor survival in gastric cancer. Br. J. Cancer 1999; 81; 1392±1397.
  27. International Union Against Cancer. TNM classi®cation of malignant tumours. In Hermanek P and Sobin LH eds. TNM classi®cation of malignant tumours, 4th edn, 2nd rev. Berlin: Springer-Verlag, 1992; 47±50.
  28. Oota K, Sobin LH. Histological typing of gastric and oesophageal tumours. World Health Organisation. International histological classi®cation of tumours. Berlin: Springer Verlag, 1990.
  29. Lauren P. The two histological main types of gastric carcinomas: diffuse and so-called intestinal-type carcinoma. Acta Pathol. Microbiol. Immunol. Scand. 1965; 64; 31±49.
  30. Gabbert HE, Meier S, Gerharz CD, Hommel G. Incidence and prognostic signi®cance of vascular invasion in 529 gastric cancer patients. Int. J. Cancer 1991; 49; 203±207.
  31. Mu È ller W, Schneiders A, Meier S, Hommel G, Gabbert HE. Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma. Br. J. Cancer 1996; 74; 759±765.
  32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53; 457±81.
  33. Kalb¯eisch JD, Prentice RL. The statistical analysis of failure data, 1st edn. New York: Wiley, Inc., 1980.
  34. Van Nhieu JT, Renard CA, Wie Y, Cherqui D, Zafrani ES, Buendia MA. Nuclear accumulation of mutated b-catenin in hepatocel- lular carcinoma is associated with increased cell proliferation. Am. J. Pathol. 1999; 155; 703±710.
  35. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of b- catenin in anaplastic thyroid carcinoma. Cancer Res. 1999; 59; 1811±1815.
  36. Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S. b-catenin mutation in carcinoma of the uterine endometrium. Cancer Res. 1998; 58; 3526±3528.
  37. Candidus S, Bischoff P, Becker KF, Ho ȯer H. No evidence for mutations in the a-and b-catenin genes in human gastric and breast carcinomas. Cancer Res. 1996; 56; 49±52.
  38. Park WS, Oh RR, Park JY et al. Frequent somatic mutations of the b-catenin gene in intestinal-type gastric cancer. Cancer Res. 1999; 59; 4257±4260.
  39. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. b-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 1997; 16; 3797±3804.
  40. Horii A, Nakatsuru S, Miyoshi Y et al. The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. Cancer Res. 1992; 52; 6696±6698.
  41. Ogasawara S, Maesawa C, Tamura G, Satodate R. Lack of mutations of the adenomatous polyposis coli gene in oesopha- geal and gastric carcinomas. Virchows Arch. 1994; 424; 607±611.
  42. Maesawa C, Tamura G, Suzuki Y et al. The sequential accumulation of genetic alterations characteristic of the colorectal adenoma-carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. J. Pathol. 1995; 176; 249±258.
  43. Gabbert HE. Mechanisms in tumour invasion: evidence from in vivo observations. Cancer Metastasis Rev. 1985; 4; 293±309.
  44. Yonemura Y, Nojima N, Kaji M et al. E-cadherin and urokinase- type plasminogen activator tissue status in gastric carcinoma. Cancer 1995; 76; 941±953.